We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.76 | 64.79 | 65.53 | 64.33 | 65.51 | 7,822,720 | 00:54:54 |
From May 2019 to May 2024
By Rory Gallivan
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that it has submitted an application to the European Medicines Agency to widen the uses for which its pulmonary arterial hypertension treatment Ambrisentan can be marketed.
Glaxo said its application seeks "to extend the current therapeutic indication to include its use in initial combination therapy for patients with pulmonary arterial hypertension."
The application is based on the results of a study conducted with biotechnology company Gilead Sciences Inc (GILD), Glaxo said.
At 1205 GMT, Glaxo shares were down 4 pence, or 0.3%, at 1,382 pence, valuing the company at 67.2 billion pounds ($105.4 million).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
